Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is unacceptable concludes the July issue of Drug and Therapeutics Bulletin (DTB).

But that is what the National Institute for Health and Clinical Excellence (NICE), the body responsible for guiding the NHS on which treatments to use, is proposing.

Ranibizumab (Lucentis) and pegaptanib (Macugen) are licensed in the UK for the treatment of neovascular (wet) age-related macular degeneration. A third drug bevacizumab (Avastin) is also used, but not licensed for the condition.

In wet age-related macular degeneration, in which fine central vision is progressively lost, new blood vessels grow beneath the retina, a process stimulated by vascular endothelial growth factor (VEGF). All three drugs potentially block the effects of VEGF.

Wet age-related macular degeneration is the third most common cause of blindness worldwide. It affects around 2.3% of over-65s in Europe. In the UK around 26,000 people develop it each year and 245,000 are blind or visually impaired because of it.

After a thorough examination of published clinical trial data, DTB concludes that there is good evidence that both ranibizumab and pegaptanib prevent further deterioration in vision in most patients. Ranibizumab improved vision in a third.

The NICE draft guidance on use of ranibizumab and pegaptanib was published in June. It recommends ranibizumab for only about 20 per cent of patients with wet age-related macular degeneration, restricting its use to those in whom both eyes are affected and then to the better seeing eye.

Final guidance is due in September.

DTB says: We believe that policies that dictate that patients must go blind in one eye before being given treatment for the other are unacceptable.

It continues: Pegaptanib and ranibizumab need to be made available for use thr
'"/>




Page: 1 2
Related medicine news :

1. OPPI Opposes Draft National Pharmaceuticals Policy
2. Smoking Ban Draft Is Put For Consultation
3. Kerala Drafts a New Health Tourism Policy
4. National Lung Study in the process
5. Indian Nationals with Foreign Medical Degrees can now practice in India
6. Hepatitis B Vaccine To Be Included In National Immunization Programme
7. UK Govt Says On Course For National Chlamydia Screening
8. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
9. India extends National TB Control Program
10. President and Founder of National Obesity Forum Resigns
11. Hwang Woo Suk Suspended By Seoul National University